Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.


Journal

BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449

Informations de publication

Date de publication:
12 11 2019
Historique:
received: 05 08 2019
accepted: 21 10 2019
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 31 3 2020
Statut: epublish

Résumé

The management of Klebsiella pneumoniae carbapenemase producing (KPC) infections represents a major challenge. Several safety and efficacy concerns are shared by available antibiotics used in KPC infections, leading to the occurrence of serious adverse drug reactions (ADRs), with ceftazidime-avibactam possibly showing a more favourable risk-benefit profile. We investigated the potential impact of resistance on ADR reports in countries with different prevalence of KPC isolates (Italy vs. United Kingdom [UK]), and described safety profile of newer and older antibiotics used in KPC infections. Three spontaneous reporting systems (SRSs) with different features (Italy, UK and worldwide FAERS) were used to describe safety profiles of colistin, meropenem, tigecycline, gentamicin and ceftazidime-avibactam in terms of System Organ Class and Preferred Term level. ADRs were plotted with prevalence of KPC isolates in Italy and UK. A comparison between before-after the KPC outbreak period (1999-2008 vs. 2009-2018) of overall and serious ADRs for selected antibiotics in each SRS was performed. Relationship between total and serious number of ADR reports per year and KPC isolates per year after KPC outbreak (2009-2017) was investigated for both Italy and UK. A total of 16,329 ADR reports were collected in the three SRSs, with meropenem (42.6%) and gentamicin (36.9%) having the highest number of reports. Significant increase in total and serious ADR reports after the KPC outbreak compared to previous 10 years was found for colistin, meropenem and gentamicin (p < 0.01). No significant increase in tigecycline ADRs was reported in FAERS and UK database. Unexpected safety signals involving selected antibiotics were not detected. Significant positive relationship between overall and serious ADR reports and KPC isolates per year for both Italy (p < 0.01; p = 0.005) and UK (p = 0.032; p = 0.013) was found. KPC outbreak led to significant increase in ADRs to selected antibiotics, and a close relationship with antimicrobial resistance was found, both in countries with high and low resistance rate. New safety signals were not detected for selected agents. Active surveillance should be maintained to promptly identify unexpected safety issues.

Sections du résumé

BACKGROUND
The management of Klebsiella pneumoniae carbapenemase producing (KPC) infections represents a major challenge. Several safety and efficacy concerns are shared by available antibiotics used in KPC infections, leading to the occurrence of serious adverse drug reactions (ADRs), with ceftazidime-avibactam possibly showing a more favourable risk-benefit profile. We investigated the potential impact of resistance on ADR reports in countries with different prevalence of KPC isolates (Italy vs. United Kingdom [UK]), and described safety profile of newer and older antibiotics used in KPC infections.
METHODS
Three spontaneous reporting systems (SRSs) with different features (Italy, UK and worldwide FAERS) were used to describe safety profiles of colistin, meropenem, tigecycline, gentamicin and ceftazidime-avibactam in terms of System Organ Class and Preferred Term level. ADRs were plotted with prevalence of KPC isolates in Italy and UK. A comparison between before-after the KPC outbreak period (1999-2008 vs. 2009-2018) of overall and serious ADRs for selected antibiotics in each SRS was performed. Relationship between total and serious number of ADR reports per year and KPC isolates per year after KPC outbreak (2009-2017) was investigated for both Italy and UK.
RESULTS
A total of 16,329 ADR reports were collected in the three SRSs, with meropenem (42.6%) and gentamicin (36.9%) having the highest number of reports. Significant increase in total and serious ADR reports after the KPC outbreak compared to previous 10 years was found for colistin, meropenem and gentamicin (p < 0.01). No significant increase in tigecycline ADRs was reported in FAERS and UK database. Unexpected safety signals involving selected antibiotics were not detected. Significant positive relationship between overall and serious ADR reports and KPC isolates per year for both Italy (p < 0.01; p = 0.005) and UK (p = 0.032; p = 0.013) was found.
CONCLUSION
KPC outbreak led to significant increase in ADRs to selected antibiotics, and a close relationship with antimicrobial resistance was found, both in countries with high and low resistance rate. New safety signals were not detected for selected agents. Active surveillance should be maintained to promptly identify unexpected safety issues.

Identifiants

pubmed: 31718688
doi: 10.1186/s40360-019-0364-0
pii: 10.1186/s40360-019-0364-0
pmc: PMC6852729
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azabicyclo Compounds 0
Bacterial Proteins 0
Drug Combinations 0
Gentamicins 0
avibactam, ceftazidime drug combination 0
Tigecycline 70JE2N95KR
Ceftazidime 9M416Z9QNR
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6
Meropenem FV9J3JU8B1
Colistin Z67X93HJG1

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

65

Références

Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
JAMA. 2019 Jan 15;321(2):188-199
pubmed: 30644987
Expert Rev Anti Infect Ther. 2014 Apr;12(4):397-400
pubmed: 24597542
Clin Microbiol Infect. 2018 Feb;24(2):133-144
pubmed: 28893689
J Intern Med. 2015 May;277(5):501-12
pubmed: 25556628
Front Microbiol. 2016 Jun 13;7:895
pubmed: 27379038
Lancet Infect Dis. 2009 Apr;9(4):228-36
pubmed: 19324295
Expert Opin Drug Saf. 2012 May;11(3):381-99
pubmed: 22220627
Diagn Microbiol Infect Dis. 2019 May;94(1):41-49
pubmed: 30635223
Virulence. 2017 May 19;8(4):403-416
pubmed: 27384881
Clin Infect Dis. 2019 Jan 18;68(3):355-364
pubmed: 29893802
MMWR Morb Mortal Wkly Rep. 2016 Mar 11;65(9):235-41
pubmed: 26963489
Curr Opin Infect Dis. 2012 Dec;25(6):626-33
pubmed: 23041772
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii3-4
pubmed: 23772044
Br J Clin Pharmacol. 2018 Feb;84(2):223-238
pubmed: 28940715
Curr Opin Infect Dis. 2018 Dec;31(6):566-577
pubmed: 30379732
Pharmacotherapy. 2013 Jan;33(1):63-8
pubmed: 23307547
Nutr Metab Cardiovasc Dis. 2018 Jun;28(6):533-542
pubmed: 29625780
Biol Pharm Bull. 2012;35(6):967-70
pubmed: 22687540
Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61
pubmed: 11257029
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
New Microbiol. 2015 Apr;38(2):121-36
pubmed: 25915055
Drugs. 2003;63(14):1511-24
pubmed: 12834367
Target Oncol. 2019 Apr;14(2):205-221
pubmed: 30927173
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Drugs Real World Outcomes. 2018 Jun;5(2):91-99
pubmed: 29476420
Drug Saf. 2016 Jan;39(1):59-68
pubmed: 26446144
Drug Saf. 2007;30(8):657-68
pubmed: 17696578
Clin Microbiol Infect. 2012 May;18(5):413-31
pubmed: 22507109

Auteurs

Milo Gatti (M)

Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy.

Emanuel Raschi (E)

Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. emanuel.raschi@unibo.it.

Fabrizio De Ponti (F)

Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH